CDKN2A and oropharynx cancer: A recent large international study on 7,654 patients with oropharyngeal cancer showed that detection of p16INK4a overexpression should be complemented with testing for HPV DNA or HPV mRNA to reduce the risk of misclassification of HPV-non-attributable tumors (11).